COVID-19 has had far-reaching social, economic and regulatory impacts. Nearly all companies (private and public, large and small) have had reason to more frequently convene their boards of directors to review and monitor...more
6/22/2020
/ Board of Directors ,
Clinical Trials ,
Coronavirus/COVID-19 ,
Corporate Governance ,
Derivative Suit ,
Food and Drug Administration (FDA) ,
Internal Controls ,
Life Sciences ,
Oversight Duties ,
Pharmaceutical Industry ,
Research and Development
This first installment in a series of Orrick publications is dedicated to the exploration of trends in venture investment across life sciences. For this issue, we offer historical context to inform our trend analysis and...more